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Specifications for pharmaceutical products are laid
down and approved as part of the marketing authorisa-
tion procedures. Within the European Union, the mar-
keting authorisations for medicines have since 1995
been granted through the centralised procedure, the mu-
tual recognition procedure or through national authori-
sation. Although many innovative products go through
the centralised procedure, the mutual recognition of na-
tional authorisations is more frequent a way to obtain
marketing authorisation. In Finland, about one of every
four medicinal products were centrally authorised last
year. When medicinal products enter the market, the au-
thorities perform laboratory tests to control that they
really comply with the specifications imposed on them.
Since 1999, there has been an operation procedure,
co-ordinated by EDQM (European Department for the
Quality of Medicines), for sampling and testing of EU
centrally authorised products. This is done in accor-
dance with a program adopted by EMEA (European
Agency for the Evaluation of Medicinal Products). Each
product is examined by two laboratories, which are
members of the European Network of Official Medi-
cines Control Laboratories. That way the whole range
of expertise of all member state laboratories can be fully
utilised, while overlapping work and sampling can be
avoided. The above, however, applies only to medicinal
products that have undergone the centralised marketing
authorisation procedure.
Due to the positive experiences from the inter-labo-
ratory collaboration, it is now planned to extend it to
the medicinal products authorised through the mutual
recognition procedure. In December 2000, it was agreed
at a meeting held in Strasbourg to initiate a trial project.
This trial phase is now nearing its end, and an evalua-
tion meeting is due to be convened early in the year
2002. The Pharmaceutical Laboratory of the National
Agency for Medicines has actively participated in the
planning and testing of new procedures. The work-shar-
ing now under elaboration will boost quality control, as
a laboratory can analyse samples coming from various
parts of Europe in batches, instead of several national
laboratories analysing each medicinal preparation sepa-
rately. The procedure also enables comparisons between
the results of the samples tested.
At present, a considerable part of the working hours
of medicines control laboratories is spent on acquiring
materials, supplies, and instructions and further on
method validation and documentation. Taking several
samples from different countries and analysing them si-
multaneously increases control efficiency, because the
time spent on analysing a single sample, or a set of three
or four samples, does not differ significantly.
This collaboration presupposes, however, that the
mutual approval of results does not give rise to any
problems for the participating authorities. Developing
quality systems for the laboratories and accreditation of
methods serve to increase the reliability and credibility
of test results. Verifying the quality control test results
in another laboratory would be desirable, at least until
all participating laboratories have received accredita-
tion. The Pharmaceutical and Biological Laboratories of
the National Agency for Medicines are well equipped to
participate in European quality control collaboration,
regardless of in what direction the system develops. The
laboratories have a quality system based on the stan-
dard EN ISO/IEC 17025, and their most important
methods have been accredited by the Finnish Accredita-
tion service, FINAS.
Tom Wikberg
PHD (PHARM), LABORATORY MANAGER
Pharmaceutical Department
National Agency for Medicines
Collaboration boosts quality control in Europe
Editorial
Summary 
33-39.tulostus  9.2.2002  14:02  Page 33
34 TABU 1.2002
It is characteristic of patients with
moderate persistent “step 3” asthma
(1,2) to have symptoms of asthma
even daily, despite the use of low to
moderate doses of inhaled steroids
(beclomethasone or budesonide 
< 1,000 microg/day or fluticasone 
< 500 microg/day). Several doses of
rescue medication are required week-
ly or even daily. Low and/or variable
peak expiratory flow (PEF) values or
low forced expiratory volume in one
second (FEV1) are often revealed by
pulmonary function tests. The asth-
ma is not adequately controlled and
the treatment should be made more
effective. The alternatives consist of
increasing the dose of inhaled
steroids or adding a long-acting be-
ta-2-agonist, a leukotriene antagonist
or theophylline to the treatment.
Find out
Before changing the medication find
out
• whether the patient is using in-
haled steroids in accordance with
the instructions given
• whether the inhalation technique
is correct
• if there are any deteriorating fac-
tors in the patient's environment
(e.g. pets, changes in the working
environment, hobbies)
If the points above give no cause for
concern, or the circumstances cannot
be changed despite attempts to do
so, then the medication should be al-
tered to make it more effective.
Should the dose of inhaled
steroids be increased?
Increasing the dose of steroids could
evoke several different anti-inflam-
matory effects which smaller doses
are unable to produce, so in princi-
ple increasing the dose appears a
sensible approach. 
A statistically significant dose-re-
sponse relationship has been report-
ed in some studies (e.g. 3,4), but,
surprisingly, an important difference
only occurred between the smallest
and the largest dose of budesonide
(200–1,600 microg/day) when morn-
ing PEF values or FEV1 (4) were
measured. No important differences
between the doses were found when
evening PEF values, day- or night-
time symptom scores or the use of
rescue medication were measured.
Similar results have been obtained
with beclomethasone and fluticasone
in spite of even an 8 to 20-fold dif-
ference between the lowest and the
highest doses of the drug (5,6). But,
in respect of all the variables studied,
the effect of the smallest dose of flu-
ticasone (50 microg/day), for in-
stance, was already markedly differ-
ent from that of the placebo (5). A
meta-analysis (N=2,324) (7) of the
dose-response relationship of flutica-
sone in the treatment of asthma con-
cluded that 80% of the benefits of a
large dose of fluticasone (1,000 mi-
crog/day) were already obtained at a
dose level of 70–170 microg/day and
90% of the benefits at a dose level of
100–250 microg/day. The maximum
effect of fluticasone was obtained
with a dose level of about 500 mi-
crog/day. In another meta-analysis
(8) fluticasone was found to improve
the results of pulmonary function
tests and reduce the symptom scores
and the need for the rescue beta-2-
agonist use at all dose levels studied
(100–1,000 microg/day) as com-
pared with the placebo. Even in this
case, the only important difference
was between the doses of 100 and
1,000 microg/day. A meta-analysis
(9) made of the studies on beclo-
methasone arrives at results pointing
to the same direction. Budesonide
(10) in mild or moderate asthma did
not result in any significant dose-re-
sponse relationship between dose
levels of 200–1,600 microg/day
when FEV1, morning PEF values,
symptom scores or the use rescue
medication were measured. How-
ever, increasing the dose of budeson-
ide from 200 microg/day to 800 mi-
crog/day in patients with moderate
to severe asthma does lower the
number of exacerbations of asthma.
It seems therefore that the small and
moderate doses of inhaled steroids
used clinically nowadays are found
in the flat part of the dose-response
curve.
In the treatment of asthma, pul-
monary function tests or asthma
symptoms do not always give a reli-
able picture of the concomitant in-
flammation of the bronchi. Based on
the limited studies published so far, it
appears that the additional anti-in-
flammatory effect achieved by dou-
bling the dose of inhaled steroids is
generally not even statistically signif-
icant when inflammation is assessed
by means such as hyperreactivity,
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eosinophils, or exhaled nitric oxide
(9,11-13).
The adverse effects of inhaled
glucocorticoids are generally rela-
tively mild. However, the risk of sys-
temic adverse effects increases as the
dose of inhaled steroids is increased.
Adrenal suppression only seldom ne-
cessitates supplementation therapy,
but it does reflect the possibility that
inhaled glucocorticoids can cause
other systemic adverse effects (14).
The risks of reduced cortisol pro-
duction and reduced bone density
are markedly increased when the
daily doses of beclomethasone
dipropionate and budesonide exceed
1,500 microg and that of fluticasone
propionate exceeds 750 microg (15).
Nevertheless, the risk of systemic
adverse effects varies individually.
Even though the risk of adverse ef-
fects and their significance in long-
term treatment remain largely un-
known so far, attempts to use the
smallest effective dose possible are
certainly sensible.
Should a long-acting beta-2-
agonist be combined to the
treatment?
The bronchodilatory effect of long-
acting beta-2-agonists, formoterol
and salmeterol, lasts approximately
12 hours. Combining one of these
with the steroid medication of asth-
ma patients has been found to im-
prove the patient's quality of life
and the results of pulmonary func-
tion tests, decrease the night-time
symtoms and protect from bronchial
contraction caused by exercise or
several unspecified factors more ef-
fectively than does a placebo or a
regular use of short-acting beta-2-
agonists (16). In recent years, several
studies have been published in
which the addition of a long-acting
beta-2-agonist has been compared
with increasing the dose of inhaled
steroids in asthma patients in whom
symptoms and/or findings typical of
active asthma are found despite the
administration of low or moderate
doses of inhaled steroids.
Salmeterol
Adding salmeterol to the medication
as against increasing the dose of in-
haled steroids (doubling the dose, at
least) have been compared in a re-
cent meta-analysis (17). Adding sal-
meterol to the medication improves
both the PEF values and the FEV1
significantly better than does in-
creasing the dose of inhaled steroids
after both 3 months and 6 months
of treatment. The addition of salme-
terol to the treatment improved the
PEF values by 22–27.7 L/min more
and the FEV1 0.08–0.1 L more than
the increase in the dose of inhaled
steroids did. The added salmeterol
also increased significantly the num-
ber of symptom-free days and nights
and the number of days and nights
free of rescue medication use.
Formoterol
A one-year-long randomised double-
blind study, FACET, examined the
effect of two different doses of in-
haled steroids (budesonide 200 and
800 microg/day) and of the addition
of a long-acting beta-2-agonist (for-
moterol 12 microg x 2 /day) to the
treatment in patients with sympto-
matic asthma despite the use of in-
haled steroids (18). A statistically
significant improvement of both
FEV1 and morning PEF values was
obtained by a four-fold increase in
the dose of inhalation steroids.
Adding formoterol to the treatment
improved both the FEV1 and morn-
ing PEF values. The improvement
produced by this combination is sig-
nificantly larger than that following
the increase in the dose of inhaled
steroids. Adding formoterol to the
medication also significantly de-
creased the daytime and nighttime
symptoms and the need for symp-
tom-relieving medication. An in-
crease in dose of inhalation steroids
also had a similar, although smaller
effect. The adverse effects did not
differ significantly to the advantage
of either medication.
Exacerbations of asthma
Eosinophilic bronchitis is a typical
feature of asthma. The biggest con-
cern in the introduction of long-act-
ing beta-2-agonists has been that
they might mask an increase in the
underlying inflammation in asthma.
When the dose of the anti-inflamma-
tory drug is not increased the under-
lying inflammation associated with
asthma may be augmented and
might finally result in increased
number or more severe exacerba-
tions of the asthma. The effect of
addition of a long-acting beta-2-ago-
nist on asthmatic inflammation has
been examined in four studies (19-
22). Three of these did not reveal
any significant masking of the in-
flammation.
If the addition of a long-acting
beta-2-agonist to the medication
would mask the inflammation un-
derlying the asthma, it could be ex-
pected to increase the number of ex-
acerbations of asthma and/or make
them more severe. Compared with
an increase in the dose of inhaled
steroids, the addition of salmeterol
to the medication produced 2.7%
fewer cases of exacerbation of asth-
ma during 3–6 months of treatment
(17), i.e. the addition of salmeterol
did not increase the patient's risk of
exacerbations of asthma. In the
FACET study (18), a four-fold in-
crease in the dose of budesonide de-
creased the number of exacerbations
of asthma more than the addition of
formoterol. The best result was ob-
tained by increasing the dose of
steroids simultaneously with the ad-
dition of formoterol: the number of
exacerbations of asthma was de-
creased by about 60%. When the
exacerbations reported in the
FACET study were analysed sepa-
rately (23), it was found that the ad-
dition of formoterol to the medica-
tion did not alter the changes in PEF
values or symptom scores found
during exacerbation. The important
result of this finding is that PEF val-
ues can still be used in a guided self-
management of asthma even in pa-
tients using long-acting beta-2-ago-
nists. Guided self-management of
asthma in itself decreases the num-
ber of exacerbations of asthma con-
siderably (24). Taken together, there
is no reliable proof that long-acting
beta-2-agonists would have a signifi-
cant additional anti-inflammatory
activity in the treatment of asthma,
but nor is there proof of the risk of
significant masking of the inflamma-
tion underlying the asthma, if the
patient is and remains on inhaled
steroid therapy.
Should a leukotriene agonist be
added to the medication?
A new group of drugs has been in-
troduced into the treatment of asth-
ma, cysteinyl leukotriene (CysLT1)
receptor antagonists (montelukast
and zafirlukast). The position of
these drugs in the treatment of asth-
ma has not yet been fully established
(1,2). Leukotriene antagonists de-
crease bronchial constriction and
improve pulmonary function. They
also have a slight anti-inflammatory
effect. Glucocorticoids have been re-
ported to diminish the production of
cysteinyl leukotrienes only slightly
or not at all. By the addition of a
leukotriene antagonist to the med-
ication of asthma patients we would
produce a preventive effect in the
transmitter system on which the in-
haled steroid has a only slight effect
or no effect at all (25). But is it suc-
cessful? In patients who had moder-
ate symptomatic asthma despite be-
ing on inhaled steroid therapy, the
addition of montelukast (10 mg/day)
to the medication was compared
with a placebo (26). The addition of
montelukast improved the FEV1 by
0.14 L and morning PEF values by
10.4 L/min, and there was a statisti-
cally significant decrease in the num-
ber of days of exacerbation and in
the daytime asthma symptom scores.
But, on the other hand, there was no
statistically significant difference in
the use of rescue medication,
evening PEF values, the number of
asthma attacks and the patient's
own assessments. In patients who
had symptomatic chronic asthma
(27) despite inhaled steroid therapy
and other medication (some patients
were on a long-acting beta-2-ago-
nists and/or theophylline), mon-
telukast (10 mg/day) was no better
than the placebo in reducing the pa-
tients' symptoms or the use of res-
cue medication or in improving the
morning or evening PEF values. No
significant benefit was proven by the
addition of montelukast to the med-
ication in this patient group, which
bore a fairly good resemblance to
patients at a normal asthma clinic
run by a specialist.
The effect of the addition of
high-dose zafirlukast (80 mg x 2)
was studied in patients who had
moderate or severe symptomatic
asthma despite inhaled steroid thera-
py (28). The addition of zafirlukast
to the medication improved the
morning PEF values and FEV1; the
reduction in the symptom scores and
in the use of rescue medication was
also superior to that achieved by the
placebo. Nevertheless, there was no
significant difference in the noctur-
nal wakenings and the symptoms of
asthma in the morning. The addition
of zafirlukast reduced the risk of ex-
acerbation of asthma (all stages of
severity) significantly, the risk rela-
tionship being 0.61 in favour of ad-
dition of zafirlukast. According to a
recent meta-analysis (29), compared
with inhaled steroids alone, the ad-
dition of a high-dose leukotriene an-
tagonist (2–4 x the normal dose in
clinical use) to the medication re-
duces the occurrence of asthma ex-
acerbations, which require a course
of treatment with steroid tablets (the
risk relationship being 0.34). The ef-
fect that normal therapeutic doses of
leukotriene antagonists nowadays in
use in Finland have on the number
of exacerbations has not been stud-
ied. In adult asthma patients with
symptoms, the addition of zafir-
lukast was no better than doubling
of the dose of inhaled steroids in re-
ducing the number of exacerbations
(29).
The addition of montelukast (10
mg x 1) has also been compared
with the addition of salmeterol (30,
31). Most measured parameters
were considerably improved by both
of these treatments. The addition of
salmeterol appeared to improve the
asthma control statistically signifi-
cantly better than the addition of
montelukast did, in respect of most
parameters studied. However, not all
symptom score parameters revealed
a difference between the treatment
groups. Similar results were obtain-
ed when comparing the addition of
salmeterol to zafirlukast (20 mg x 2)
in patients with moderate asthma
(32).
To conclude, addition of a leuko-
triene antagonist to the medication
of patients who exhibit symptoms in
spite of inhaled steroid therapy is a
feasible alternative. It remains to be
seen whether the addition of a
leukotriene antagonist is a better al-
ternative than an increase in the
dose of inhaled steroids. The clinical
significance of the difference be-
tween the addition of a long-acting
beta-2-agonists and a leukotriene
antagonist is difficult to establish.
The large individual variation in the
response to leukotriene antagonists
should also be considered in assess-
ing the benefits. Some patients find
their drugs very beneficial to them,
whereas a relatively large group of
patients have no benefit from their
antileukotriene drugs at all. Nor is
there any way of predicting who
would benefit from leukotriene an-
tagonists. 
Should theophylline be added?
The addition of theophylline to the
medication of asthma patients who
have symptoms in spite of inhaled
steroid therapy has been compared
with doubling of the dose of steroids
(budesonide or beclomethasone) in
two separate studies (33,34). The
concentration of theophylline in
both of the studies is rather low,
8.7–10.1 mg/L on average, i.e. at the
lower end of the scale of serum con-
centrations nowadays considered
therapeutic. In both studies the effi-
cacy of the addition of theophylline
to the medication corresponded to
that of the doubling of the dose of
inhaled steroids. The number of ad-
verse effects remained low by using
small doses of theophylline. In a
third study no such a significant
benefit was obtained by adding
theophylline to the medication of
asthma patients who had symptoms
and attended at a general practition-
er's consultation (35).
In conclusion
The benefits of addition of a long-
acting beta-2-agonist have proven
best, and it was shown to be more
effective than an increase in the dose
of an inhaled steroid in improving
the patient's quality of life and the
results of pulmonary function tests,
and in reducing the symptoms and
the need for rescue medication.
From a clinical point of view, the
benefit to be expected from dou-
bling the dose of an inhaled steroid
is rather small, even though it varies
individually. Especially in a situation
where the patient's problems consist
of recurring exacerbations there are
36 TABU 1.2002
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indications that an increase in the
dose of an inhaled steroid would be
of benefit. The adding of a leuko-
triene antagonist or a small dose of
theophylline to the inhaled steroid
therapy has also been found to im-
prove asthma control.
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Sleep disorders are a frequent occur-
rence and it has become commoner
to treat them with hypnotics.  In
2000, the total consumption of hyp-
notics in out- and in-patient care
was 49 daily defined doses (DDD)
per 1,000 inhabitants, whereas in
1999 the figure totalled 47 (1). In
the same year, the sales of hypnotics
at wholesale prices in Finland
reached almost 68 million FIM, in-
dicating an increase of 7% com-
pared with the previous year.
Hypnotics improve the ability to
fall asleep or prolong the duration
of sleep.  Benzodiazepines and ben-
zodiazepine-like medicinal sub-
stances are considered primary
drugs in the treatment of sleepless-
ness. They can in practice, on the
basis of their duration of action, be
grouped into short-acting, medium-
acting and long-acting substances
(Table).
In recommended therapeutic dos-
es benzodiazepines are usually well
tolerated and safe to use.  Their
long-term use easily causes depen-
dence, which is why in the treatment
of insomnia a short-term use of two
weeks is preferred. Tolerance to
their effect develops with continuous
regular use, and their efficacy is
thereby reduced.  Furthermore, hyp-
notics increase the toxicity of alco-
hol and other CNS drugs.
In view of their mechanism of
action benzodiazepine-related hyp-
notics such as zopiclone, zolpidem
and zaleplon bear a close resem-
blance to benzodiazepines.  They are
appropriate mainly for the treatment
of difficulty in falling asleep, and
seldom cause a state of confusion in
the morning.  Their sedative effect,
development of tolerance and de-
pendence, and toxicity are compara-
ble to those of the benzodiazepines,
and consequently, their temporary
use is preferred.
The consumption of hypnotics
has increased during the 1990s, es-
pecially during the latter half of the
decade (Fig. 1).  Judging by the con-
sumption figures, short-acting hyp-
notics have been taken into use in
the treatment of insomnia; in partic-
ular, the consumption of zopiclone
and zolpidem has increased.  There
has been an increase in the use of
temazepam, whereas that of ni-
trazepam has declined.  The con-
sumption of triazolam diminished
when it was removed from the
Finnish market during 1.10.1991–
13.1.1993, and the quantity issued
for out-patient care was restricted to
20 tablets at one time in 1993. The
quantity of midazolam consumed is
also dropping.
A review of the amount of hyp-
notics for out-patient care per pack-
age size reveals that the majority of
the drugs have been sold in pack-
ages sizes of 100 tablets (Fig. 2).
The sale of package sizes of 30
tablets has remained stable, and
small package sizes are used least of
all.  In the case of many of the drugs
only the 100 tablet packet falls in
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the category entitled to basic refund,
which may increase the number of
prescriptions for the larger packet.
Irrespective of the refund status, the
packet size containing 100 tablets is
the most cost-efficient one for the
user as well because the price per
tablet for the small packets has con-
siderably exceeded that for the big-
ger packages (2).
The consumption of the two
drugs sold most, temazepam and
zopiclone, also reveals the prefer-
ence for the largest packet size avail-
able on the market (Fig. 3 and 4).
In the case of both drugs, the sale of
packages containing 100 tablets has
increased, and the smallest packages
sell very little.  In the case of tem-
azepam only the 100 tablet package
falls into the basic refund category,
and the 100 tablet package of zopi-
clone is the only size of packet
which is eligible for a basic refund
irrespective of manufacturer.
According to the recommenda-
tions of the National Hypnotics
Working Group (3), a course of
treatment of insomnia with hyp-
notics should not exceed 2–4 weeks.
Any longer-term use may be a sign
of anxiety or other psychiatric disor-
der associated with insomnia, in
which case the need for medical
treatment should be reassessed.  The
preference for large packet sizes in-
dicates that hypnotics are frequently
used long-term.  Despite the higher
price, preference for the small pack-
et sizes could reduce the excess use
of hypnotics.
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